Xenon Pharmaceuticals
XENE
159 hedge funds and large institutions have $2.37B invested in Xenon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 59 increasing their positions, 47 reducing their positions, and 17 closing their positions.
197% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $5.16M
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
26% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 47
21% more capital invested
Capital invested by funds: $1.96B → $2.37B (+$408M)
3% more funds holding
Funds holding: 154 → 159 (+5)
3.22% more ownership
Funds ownership: 93.36% → 96.58% (+3.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$24.7M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$17.6M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$16.6M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.6M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Holocene Advisors
New York
|
-$23.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$16.2M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$9.84M |
| 5 |
PA
Perceptive Advisors
New York
|
-$7.33M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$24K | -132 | Closed |
|
XENE Hedge Fund Activity: Q4 2022 in Review
159 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2022, worth a combined $2.37B — up 21% from $1.96B a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new XENE positions and 17 closed out — a net gain of 5 holders — while 59 added to existing stakes and 47 trimmed.
The largest buyer was Loomis, Sayles & Company, opening a new position worth an estimated $24.7M. The largest seller was Holocene Advisors, cutting an estimated $23.2M.
- 159 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2022, up from 154 in Q3 2022.
- Funds reported $2.37B of Xenon Pharmaceuticals stock for Q4 2022, up 21% quarter-over-quarter.
- 22 funds opened new Xenon Pharmaceuticals positions in Q4 2022 and 17 closed out, a net change of +5 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2022 was Loomis, Sayles & Company, an estimated $24.7M added.
- The largest Xenon Pharmaceuticals seller in Q4 2022 was Holocene Advisors, an estimated $23.2M sold.
Based on aggregated 13F filings for Q4 2022.